Kevin Corcoran has been appointed president and chief executive officer of Lynx Therapeutics, replacing CEO Norrie Russell. Corcoran has been at Lynx for seven years and has served as vice president of operations since 1999. While there, he has worked to cement relationships with DuPont and Takara Bio, as well as Lynx’s recent service agreement with the National Cancer Institute. Corcoran also served on the development team for the company’s Massively Parallel Signature Sequencing technology and has spearheaded development of next-generation MPSS instruments. Corcoran came to Lynx from Applied Biosystems, where he held both technical and management positions.
“We believe Kevin will be an outstanding leader for Lynx as we expand the commercial reach of our MPSS technology and move our Protein ProFiler technology toward commercialization,” stated Craig Taylor, Chairman of Lynx’s board. “We are confident that Kevin’s thorough understanding of our technology, his skills at interacting with our customers, as well as his experience in directly managing our operations, will enable him to lead Lynx successfully.”
Russell, who served as CEO of Lynx since November 1999, resigned his position “to pursue other interests,” Lynx said.
The change at Lynx’s helm follows a restructuring in which the company laid off 30 percent of its staff and raised $22.6 million in new financing.
Human Genome Sciences has named Gilles Gallant as vice president of oncology. Gallant comes to HGS from Bristol-Myers Squibb Research Institute, where he worked for 10 years and most recently served as director of clinical oncology. At BMS, Gallant was the worldwide clinical project leader for Taxol and other taxane compounds. Gallant received his doctorate in medicinal chemistry from the Université de Montreal in Montreal, Canada.